20 Most Expensive Stocks Insiders Are Dumping In March

16. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Market Capitalization: $7.47 billion

Madrigal is a biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH). The company’s Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to treat MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial is evaluating Rezdiffra for treating compensated MASH cirrhosis.

For the full year 2024, the company reported net revenues of $180.1 million. No product sales were recognized during the comparable prior year period. As of Dec. 31, 2024, Madrigal had cash, cash equivalents, restricted cash and marketable securities of $931.3 million, compared to $634.1 million at Dec. 31, 2023.

In recent developments, Madrigal announced FDA approval of Rezdiffra for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

This month, five insiders, including the CFO, sold approximately $11.36 million worth of Madrigal shares at an average price of $330.33 per share. Currently, the stock trades at $338.49 per share, having gained 9.69% year-to-date and 36.70% over the past 12 months.

Ten analysts have given an average “Moderate Buy” rating on Madrigal stock with a price target of $378.44. The average price target suggests a potential upside of 11.79% from the latest price.